THOMAS MONATH to Double-Blind Method
This is a "connection" page, showing publications THOMAS MONATH has written about Double-Blind Method.
Connection Strength
0.731
-
An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011 Apr 07; 364(14):1326-33.
Score: 0.069
-
Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009 Mar 04; 27(10):1637-44.
Score: 0.059
-
Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine. 2009 Mar 04; 27(10):1645-50.
Score: 0.059
-
A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci U S A. 2006 Apr 25; 103(17):6694-9.
Score: 0.049
-
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006 Mar-Apr; 2(2):60-7.
Score: 0.049
-
Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14.
Score: 0.047
-
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine. 2005 May 09; 23(25):3301-9.
Score: 0.046
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.041
-
Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 2003 Sep; 9(9):1125-30.
Score: 0.041
-
Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg. 2002 May; 66(5):533-41.
Score: 0.037
-
Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002 Jan 15; 20(7-8):1004-18.
Score: 0.036
-
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001 Feb; 69(2):988-95.
Score: 0.034
-
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial. Lancet. 2021 01 09; 397(10269):119-127.
Score: 0.034
-
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017 10 12; 377(15):1438-1447.
Score: 0.027
-
Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial. CMAJ. 2017 Jun 19; 189(24):E819-E827.
Score: 0.027
-
Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
Score: 0.026
-
A Recombinant Vesicular Stomatitis Virus Ebola Vaccine. N Engl J Med. 2017 01 26; 376(4):330-341.
Score: 0.023
-
Exercise-induced serum enzyme elevations confounding the evaluation of investigational drug toxicity. Report of two cases in a vaccine trial. Hum Vaccin. 2005 Jan-Feb; 1(1):24-9.
Score: 0.011
-
Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002 Nov; 51(5):634-40.
Score: 0.010
-
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 1999 Apr; 116(4):804-12.
Score: 0.008